Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05795010
Other study ID # XJTU1AF2023LSK-174
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date March 30, 2023
Est. completion date September 30, 2023

Study information

Verified date March 2023
Source First Affiliated Hospital Xi'an Jiaotong University
Contact Yongchun Song, MD
Phone 0086-18991232549
Email 758327495@qq.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Patients with colorectal cancer who were confirmed as stage II general risk type in the postoperative pathological report began to be enrolled. Observe the sensitivity of the detection of micro-MRD before operation and the postoperative positive rate of this type of patients.


Description:

This observation part is about the patients with general risk stage II colorectal cancer who have received R0 resection after screening by nanofiltration criteria. Twenty milliliters of venous blood samples were reserved before surgery, and tumor tissue samples were reserved within 30 minutes in vitro during surgery. After the pathological diagnosis of the patients after surgery, they began to be enrolled. To observe the sensitivity of MRD detection in preoperative diagnosis of patients with general risk stage II colorectal cancer, and to study its positive rate one month and three months after operation.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 60
Est. completion date September 30, 2023
Est. primary completion date April 10, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - Age 18-75; - Pathologically confirmed rectal adenocarcinoma; - Pathological differentiation is highly or moderately differentiated; - The pathological stage was pT3N0, that is, invasion of the proper muscular layer of the intestinal wall without lymph node metastasis; - No new adjuvant treatment before operation - There was no vascular infiltration and nerve infiltration in postoperative pathology; - No preoperative intestinal obstruction or tumor site perforation; - No postoperative pathological margin was positive or unknown; - The distance between the pathological cutting edge and the tumor was more than 1 cm; - Invasion of mesentery of intestinal wall = 2mm; - More than 12 lymph nodes were submitted for examination; - Nonlocal recurrence and distant metastasis; - No multiple primary carcinoma of colon and rectum; - Physical condition score PS = 2 points; - Patients and their families can understand and are willing to participate in this study and provide written informed consent. Exclusion Criteria: - Multiple intestinal carcinomatosis - Previous history of malignant tumor, - There are concurrent malignant tumors in the whole body except for colorectal cancer - Colorectal cancer with preoperative anti-tumor treatment - Pregnant or lactating women - There are serious complications during or after operation, affecting the prognosis - Hepatitis B or Hepatitis C antibody positive - HIV antibody positive - Other diseases considered by the research doctor to affect the prognosis and survival - Other conditions that the research doctor believes are not consistent with this study.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
MRD test
ctDNA detection based on tumor whole exon sequencing

Locations

Country Name City State
China First Affiliated Hospital of Xian Jiaotong University Xi'an Shaanxi

Sponsors (2)

Lead Sponsor Collaborator
First Affiliated Hospital Xi'an Jiaotong University Second Affiliated Hospital of Xi'an Jiaotong University

Country where clinical trial is conducted

China, 

References & Publications (3)

Reinert T, Henriksen TV, Christensen E, Sharma S, Salari R, Sethi H, Knudsen M, Nordentoft I, Wu HT, Tin AS, Heilskov Rasmussen M, Vang S, Shchegrova S, Frydendahl Boll Johansen A, Srinivasan R, Assaf Z, Balcioglu M, Olson A, Dashner S, Hafez D, Navarro S, Goel S, Rabinowitz M, Billings P, Sigurjonsson S, Dyrskjot L, Swenerton R, Aleshin A, Laurberg S, Husted Madsen A, Kannerup AS, Stribolt K, Palmelund Krag S, Iversen LH, Gotschalck Sunesen K, Lin CJ, Zimmermann BG, Lindbjerg Andersen C. Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer. JAMA Oncol. 2019 Aug 1;5(8):1124-1131. doi: 10.1001/jamaoncol.2019.0528. Erratum In: JAMA Oncol. 2019 Jun 13;: — View Citation

Romero D. ctDNA guides omission of adjuvant chemotherapy for stage II CRC. Nat Rev Clin Oncol. 2022 Aug;19(8):493. doi: 10.1038/s41571-022-00657-7. No abstract available. — View Citation

Tie J, Cohen JD, Lahouel K, Lo SN, Wang Y, Kosmider S, Wong R, Shapiro J, Lee M, Harris S, Khattak A, Burge M, Harris M, Lynam J, Nott L, Day F, Hayes T, McLachlan SA, Lee B, Ptak J, Silliman N, Dobbyn L, Popoli M, Hruban R, Lennon AM, Papadopoulos N, Kin — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Positive rate of preoperative MRD test To observe the positive rate of preoperative MRD detection for stage II colorectal cancer six months
Secondary Positive rate of MRD test 1 month and 3 months after operation Observe the positive rate of MRD detection at 1 month and 3 months after operation for stage II colorectal cancer nine months
See also
  Status Clinical Trial Phase
Recruiting NCT04589468 - Researching the Effect of Exercise on Cancer N/A
Recruiting NCT04624555 - The Utility and Feasibility of Mt-sDNA as a Surveillance Procedure in Colorectal Cancer Survivors
Active, not recruiting NCT04007770 - Acupuncture Pilot Study for Cancer-related Cognitive Function Phase 2
Completed NCT05025748 - Ask Questions (ASQ):Implementation of a Communication Intervention N/A
Recruiting NCT05086614 - Thymosin-alpha 1 for Adjuvant Treatment After Radical Resection of High-risk Stage II and III Colorectal Cancer Phase 3